Exploring a new approach to enhance pain relief while reducing opioid risks
Official title: Mechanism and Efficacy of a Novel Opioid Adjuvant
Funded at Amalgent Therapeutics, INC. · NIH-10786389 · Data updated 2026-11-12
This study is testing a new treatment that works alongside opioids to help manage pain better while using lower doses, making it safer for people dealing with acute pain.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Amalgent Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Greenville, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $220,668 |
| NIH project number | 1R43DA059522-01 |
| Project ID | NIH-10786389 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing acute pain who may benefit from enhanced analgesic therapies.
✕Less likely to help
Patients who are not experiencing pain or those who have contraindications to opioid use may not receive any benefit from this research.
What this research studies
This research investigates a novel opioid adjuvant designed to improve pain management while minimizing the risks associated with traditional opioid use. By enhancing the efficacy of opioid analgesics, this adjuvant aims to allow for lower doses of opioids, thereby reducing the potential for adverse effects such as dependence and addiction. The study will involve clinical evaluations to assess the effectiveness and safety of this new treatment approach, providing a potential alternative for patients suffering from acute pain.
Why it matters
Potential benefit: If successful, this research could lead to safer pain management options for patients, reducing the risk of opioid dependence and improving overall treatment outcomes.
How similar studies have gone: While the approach of using adjuvants in pain management is not entirely novel, the specific adjuvant being tested has shown promising preliminary results, indicating potential for significant advancements in treatment.
Where this research is happening
-
Amalgent Therapeutics, INC.
Greenville, United States Active
Researchers
- Principal investigator: Meyn, Malcolm a — Amalgent Therapeutics, INC.
- Study coordinator: Meyn, Malcolm a
Related research
Other NIH-funded projects on the same topics.
-
Creating a new pain treatment that reduces the need for opioids
This study is exploring a new way to help people manage pain with less reliance on opioids by combining a safe medication called pramipexole with morphine, aiming to provide better pain relief while reducing the risk of addiction.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.